Lung Cancer

New research shows Onconase inhibits tumor growth in non-small cell lung cancer

Published in Cancer Weekly, November 15th, 2005

Alfacell Corporation (ACEL) announced that Intae Lee, PhD, Department of Radiology, University of Pennsylvania, presented new data on the effectiveness of Onconase (ranpirnase) against non-small cell lung cancer (NSCLC) at the 47th Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO).

Lee's presentation is entitled, "The Enhanced Efficacy of Cisplatin and Carboplatin by the RNase Onconase on A549 Human Lung Cancer Xenografts of Nude Mice."

"In these studies, we observed several events, including whether apoptosis (programmed cell death) was induced by Onconase; whether Onconase could sensitize the efficacy of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry